Voyager Therapeutics Inc (NASDAQ:VYGR) has been given a consensus recommendation of “Buy” by the fourteen brokerages that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $32.50.

Several brokerages recently commented on VYGR. BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $27.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Chardan Capital reaffirmed a “hold” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, June 21st. ValuEngine raised shares of Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Finally, Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th.

In other news, Director Glenn Pierce bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, September 12th. The stock was acquired at an average cost of $18.44 per share, for a total transaction of $92,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James A. Geraghty bought 3,000 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was purchased at an average price of $19.39 per share, with a total value of $58,170.00. Following the completion of the purchase, the director now directly owns 76,588 shares of the company’s stock, valued at approximately $1,485,041.32. The disclosure for this purchase can be found here. Insiders bought 11,000 shares of company stock valued at $205,300 in the last three months. Company insiders own 33.60% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Metropolitan Life Insurance Co. NY boosted its stake in shares of Voyager Therapeutics by 53.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $177,000 after purchasing an additional 3,157 shares during the period. MetLife Investment Advisors LLC boosted its stake in Voyager Therapeutics by 38.6% during the 2nd quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock valued at $208,000 after acquiring an additional 2,964 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Voyager Therapeutics during the 1st quarter valued at $227,000. Thompson Davis & CO. Inc. boosted its stake in Voyager Therapeutics by 187.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 11,951 shares of the company’s stock valued at $234,000 after acquiring an additional 7,800 shares during the last quarter. Finally, Hershey Trust Co. bought a new position in Voyager Therapeutics during the 2nd quarter valued at $284,000. Institutional investors and hedge funds own 89.65% of the company’s stock.

Shares of VYGR stock opened at $18.39 on Friday. Voyager Therapeutics has a one year low of $11.54 and a one year high of $31.91. The company has a market cap of $633.80 million, a P/E ratio of -6.97 and a beta of 2.89.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.13). Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. The company had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.00 million. equities research analysts expect that Voyager Therapeutics will post -3.19 EPS for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

See Also: What kind of dividend yield to CEF’s pay?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.